Navigation Links
ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results
Date:8/12/2009

armaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company whose product candidates are designed to improve the safety of existing cancer treatments. More information can be found on the Company's website at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to raise sufficient additional capital on a timely basis to submit an NDA for ANX-530, to fund operations or pre-launch activities during the FDA review period if an NDA is submitted or launch activities should an NDA for ANX-530 be approved; the risk that ADVENTRX will be unable to raise sufficient additional capital on a timely basis to continue as a going concern; the risk that ADVENTRX will seek protection under the provisions of the U.S. Bankruptcy Code; the risk that ADVENTRX will reassess the results of the ANX-530 bioequivalence study and determine to conduct additional bioequivalence studies of ANX-530, including in humans; the potential for regulatory authorities to require additional preclinical work and/or clinical activities to support regulatory filings, including prior to the submission or the approval of an NDA for ANX-530, which activities may increase the cost and timeline to NDA submission or approval; the risk the FDA will determine that ANX-530 and Navelbine(R) are not bioequivalent, including as a result of performing pharmacokinetic equivale
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Announces Consolidation of Clinical and Management Positions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  Decision Resources Group finds that ... in the United States ... penetration will be the level of savings achievable ... expected lower cost to patients. Payers plan to ... their pricing expectations in order to encourage physician ...
(Date:7/30/2014)... July 30, 2014  Replikins Ltd. today released new ... Ebola virus. Before the current outbreaks, the mean Ebola ... amino acids) between 1995 and 2002 was 1.1; the ... 2012, and sixteen-fold in 2013, thus predicting the current ... technology has been shown to be able to predict ...
(Date:7/30/2014)... 30, 2014 Sales Horizons, a leader ... blended sales training programs for companies engaged in complex ... used by thousands of salespeople over 25 years in ... program can be customized to address the unique sales ... blended sales training program consists of two parts: ...
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... (Amex: PLX ), announced today the pricing of ... stock at a,public offering price of $5.00 per share. ... to purchase up to 1,500,000 additional shares of,common stock ... is acting as sole book-running manager for this,offering. CIBC ...
... Oct. 24 , First Quarter Highlights:, - ... - Diluted EPS up 40% to $0.35 year-over-year, excluding ... related to one-time non-U.S. net tax adjustments PAREXEL ... results for the first quarter ended September 30, 2007. ...
... The Pittsburgh Life Sciences,Greenhouse (PLSG), the private/public ... a fast track for growth, announced that ... LLC, a developmental-stage,medical device company, whose goal ... probe that will alleviate the existing,limitations of ...
Cached Biology Technology:Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock 2PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 2PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 3PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 4PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 5PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 6PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 7PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 8PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 9The PLSG Invests $115,000 in Innovention Technologies, LLC 2
(Date:7/30/2014)... increase in Impact Factors for its molecular bioscience ... (Thomson Reuters, 2014) show that Clinical Science ... Biochemistry , Biochemical Society Transactions and ... their Impact Factors. The journals are owned by ... Limited. , 2014 Impact Factors (2013 Impact Factor ...
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... of iodine-125 (125I) in cancer treatment has been ... ganglia are critical for neural transmission between the ... and colleagues from Institute of Radiation Medicine, Chinese ... could be implanted into rat dorsal root ganglia ... seeds with different radioactivity (0, 14.8, 29.6 MBq) ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2F1000Research brings static research figures to life 2
... nervous control of nematode mating behavior have produced video ... a hermaphrodite. Writing in the open access journal ... the California Institute of Technology investigated the role of ... achieve an exploratory embrace. The video shows ...
... and China have gathered in Barcelona this week to report ... data from ESA and Chinese Earth observation satellites. Dragon ... of Science and Technology (MOST) of China encourages scientists ... environmental phenomena in China. ,The symposium, held in Barcelona,s World ...
... Mo. If the growing presence of computer ,geeks, ... increasingly becoming essential tools for detecting and combating skullduggery. ... advantage of these tools. Researchers also are beginning to ... of deception, known as molecular mimicry. "Molecular ...
Cached Biology News:Europe and China watching Earth together 2Computers aid in cracking deception in plants 2
... Tissue Extract Protein Array Kit is designed ... extracts. The expression of a protein in ... specific antibody. When the antibody binds the ... sensitive chemiluminescent or fluorescent signal created by ...
... is a is a bovine protein-free alternative ... is an aqueous solution that contains non-toxic ... saline), pH 6.6 - 7.2. This ... and 0.02% bromonitrodioxane as a preservative. ...
... is an aqueous-based mounting medium designed ... sections. Gel/Mount is especially recommended when ... or FluoroBlue. It can also be ... as fluorescein (FITC), Rhodamine (TMRITC) and ...
...
Biology Products: